NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.16, Zacks reports.
NRx Pharmaceuticals Stock Down 1.8%
NASDAQ NRXP traded down $0.04 during trading hours on Monday, hitting $2.15. The company had a trading volume of 726,308 shares, compared to its average volume of 1,113,704. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $5.05. The business has a fifty day simple moving average of $2.82 and a 200-day simple moving average of $2.96. The firm has a market cap of $93.84 million, a P/E ratio of -3.91 and a beta of 2.11.
Analyst Ratings Changes
Several research analysts have recently commented on the company. UBS Group reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 26th. Zacks Research lowered NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 26th. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Tuesday, August 25th. Wolfe Research started coverage on NRx Pharmaceuticals in a research note on Thursday, October 15th. They set an “outperform” rating on the stock. Finally, Wall Street Zen downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.
Get Our Latest Stock Report on NRx Pharmaceuticals
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.
Read More
- Five stocks we like better than NRx Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
